Department of Surgery, Saitama Medical Center, Dokkyo Medical University, Saitama, Japan.
Department of Surgery, Saitama Medical Center, Dokkyo Medical University, Saitama, Japan
In Vivo. 2021 Jan-Feb;35(1):437-445. doi: 10.21873/invivo.12276.
The aim of the present study was to explore the association between CD133 expression and postoperative relapses in patients with locally advanced rectal cancer (LARC) who received neoadjuvant chemotherapy (NAC).
We retrospectively examined 52 patients with LARC (cT3-4, Nany, M0) who received oxaliplatin-based NAC before surgery. CD133 expression was evaluated using immunohistochemistry and divided into low and high expression groups.
High CD133 expression was observed in 22 patients (42.3%). Patients with high CD133 expression had more frequent vessel invasion and relapse than those with low CD133 expression (p=0.013 and p=0.036, respectively). Comparing the low with high CD133 expression groups, the 4-year relapse-free survival rates were 82.2% vs. 46.3% (p=0.009). Multivariate analysis indicated that CD133 expression was an independent risk factor for relapse (HR=3.138; 95%CI=1.046-9.412; p=0.041).
CD133 expression may be a predictive biomarker for postoperative relapse in patients with LARC who received NAC before surgery.
本研究旨在探讨接受新辅助化疗（NAC）的局部晚期直肠癌（LARC）患者中 CD133 表达与术后复发的关系。
我们回顾性分析了 52 例接受奥沙利铂为基础的 NAC 治疗的 LARC 患者（cT3-4，Nany，M0）。采用免疫组织化学法检测 CD133 表达，并分为低表达和高表达组。
22 例（42.3%）患者 CD133 高表达。与 CD133 低表达患者相比，高表达患者更易发生脉管侵犯和复发（p=0.013 和 p=0.036）。低与高 CD133 表达组的 4 年无复发生存率分别为 82.2%和 46.3%（p=0.009）。多因素分析表明，CD133 表达是复发的独立危险因素（HR=3.138；95%CI=1.046-9.412；p=0.041）。
CD133 表达可能是接受 NAC 治疗的局部晚期直肠癌患者术后复发的预测生物标志物。
